GlobeNewsWire
26 Aug 2026, 20:05 UTC · 3w ago
Verdict
Headline takes no side. We score IDXG +0.30 across three claims — moderately bullish.
+0.30moderately bullish
More positive than 57% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Interpace Biosciences is implementing a 1-for-5 reverse stock split to meet the minimum bid price requirement for a proposed Nasdaq uplisting.
More positive than 63% of claims this week
The company acknowledges that meeting the bid price requirement does not guarantee a Nasdaq listing, as other criteria like the $15 million market value of unrestricted shares must also be met.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 71% of claims this week
The reverse stock split will reduce the number of outstanding common shares from approximately 27.7 million to 5.5 million effective August 27, 2026.
Near neutral — 99% of claims this week are stronger
Which stocks this story touches
More positive than 57% of ticker scores this week
The company is implementing a reverse stock split as a strategic move to meet requirements for a Nasdaq uplisting to attract more investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
3h ago
−10.2%
Price is moving against the score
$6.51 vs $7.25 close before publication (Aug 26) · not market-adjusted
IDXG chart →
